Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead's cash tender offer for CymaBay Therapeutics, Inc. expired at 11:59 p.m. on March 8, 2024. On February 22, 2024, Gilead and CymaBay filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

Novartis

Pfizer

Gilead is diversifying its business, and yet the stock trades near recent lows and pays a solid dividend. Novartis has a new look with its spinoff of Sandoz but remains a solid pick for income investors.

3 Dividend Stocks to Buy Hand Over Fist in March

Ameren

Federal Agricultural

Allegion

Ares Management

Cogent Communications Holdings

Canadian Natural Resources

CSG Systems International

Coterra Energy

Domino's Pizza

Essent Group

Franco-Nevada C

Gold Fields Ltd.

Gaming and Leisure Properties

Horace Mann Educators

Intercontinental Exchange

Kforce

Coca-Cola

LeMaitre Vascular

Merchants Bancorp

NewMarket

NorthWestern

Universal Display

Thirty-nine companies, including Coca-Cola and Telephone and Data Systems, are raising their dividends.

39 Upcoming Dividend Increases Including 2 Dividend Kings

Gilead (GILD) reported earnings 30 days ago. What's next for the stock?

Why Is Gilead (GILD) Down 2.4% Since Last Earnings Report?

Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.

Gilead (GILD) & MRK's HIV Oral Combo Shows Efficacy in Phase II

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) for a broad range of people with HIV, including those with HIV/hepatitis B (HBV) coinfection and HIV/tuberculosis (TB) coinfection. These data and other studies supporting the important role of Biktarvy in the HIV treatment landscape were.

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Merck

FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor. These late-breaking data were presented during an oral session at the 31st Conference on.

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Merus

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the use of Merus' proprietary Triclonics® platform along with Gilead's oncology expertise to research and develop multiple, separate preclinical research programs. Merus is a clinical-stage onco.

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline. The latest results explore clinical outcomes from a study evaluating an investigational combination regimen of bictegravir and lenacapavir, new findings from a study evaluating the investigational combination of lenacapavir with broadly neutralizing antibodies (bNAbs), and new proof-of-concept data on.

Gilead's Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. (NASDAQ:GILD ) TD Cowen 44th Annual Health Care Conference March 5, 2024 12:50 PM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Welcome, and good afternoon, everyone. Welcome again to TD Cowen's 44th Annual Healthcare Conference, Day 2.

Gilead Sciences, Inc. (GILD) Presents at TD Cowen 44th Annual Health Care Conference (Transcript)

RedHill Biopharma

The U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively by ASPR/BARDA and NIH/NIAID, in collaboration with Battelle[1], have selected opaganib for evaluation as a potential medical countermeasure (MCM) against Sulfur Mustard exposure Opaganib, a novel oral small molecule, is the first sphingosine kinase-2 ( SPHK2) inhibitor investigational drug targeting sphingolipid metabolism to be evaluated as a chemical countermeasure Selection for the therapeutic testing/screening program, following opaganib's previous acceptance into the Radiation and Nuclear Countermeasures Program (RNCP) for Acute Radiation Syndrome (ARS), provides the potential to see broad activity across both radiation and Sulfur Mustard injuries Opaganib has five-year shelf-life and is easy to administer and distribute for use against potential chemical weapon attack, if approved by the U.S. Food and Drug Administration (FDA) Opaganib is being developed for multiple additional indications, including COVID-19, acute respiratory distress syndrome (ARDS) and oncology TEL AVIV, Israel and RALEIGH, N.C. , March 5, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Aurora Cannabis

AngioDynamics

APA Corporation

BioNTech SE

Xcel Energy

Ordinarily, you'll want to avoid excessively red-stained ideas. Although certain exceptions might be made for these oversold stocks ready for rebound.

Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound

In the latest trading session, Gilead Sciences (GILD) closed at $72.31, marking a +0.29% move from the previous day.

Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. HIV treatment resistance is permanent and irreversible, which can jeopardize futur.

U.S. FDA Approves Expanded Indication for Gilead's Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

SPDR Bloomberg 1-3 Month T-Bill ETF

Cisco Systems

SPDR Dow Jones Industrial Average ETF

Invesco Russell 1000 Equal Weight ETF

Entergy

iShares 7-10 Year Treasury Bond ETF

International Paper

ARK Israel Innovative Technology ETF

Invesco QQQ

Invesco S&P 500 Equal Weight ETF

SPDR S&P 500 ETF Trust

iShares 20+ Year Treasury Bond ETF

Verizon

Rob Isbitts discusses his ROAR Score, which measures reward opportunity and risk in the market.

Don't Rely On Past Performance

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new clinical data and real-world evidence (RWE) from its antiviral research and development programs at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) taking place from March 3-6. The data from nearly eighty studies across HIV, COVID-19 and viral hepatitis include late-breaking data, four oral presentations, and reflect Gilead's commitment to addr.

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

AbbVie

Eli Lilly

AbbVie is a Dividend King that's poised to soon return to robust growth. Eli Lilly's dividend is growing rapidly but is overshadowed by its tremendous stock gains.

3 Dividend Stocks That Are No-Brainer Buys Right Now

Analysts have great expectations for Gilead Sciences over the next 12 months. The biotech has an attractive valuation, a juicy dividend, several drugs with solid momentum, and plenty of cash.

History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Goodyear Tire & Rubber

PayPal

During stock market ups and downs, identifying the next big players breeding massive value growth potentials is similar to finding a pearl in a vast ice lake. Among the multitude of options, certain market giants stand out; they are ready to embark on monumental rallies.

Stock Alert: 3 Market Giants on the Brink of Monumental Rallies

BEIJING--(BUSINESS WIRE)-- #Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen's extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibod.

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Amgen

The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing radiation  Opaganib is the first selective sphingosine kinase-2 ( SPHK2) inhibitor investigational drug targeting sphingolipid metabolism for the treatment of radiation-induced inflammation Opaganib, a novel oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute, supporting potential central government stockpiling for use as radioprotection therapy in mass casualty radiological or nuclear incidents, if approved by the FDA Opaganib is being tested as a potential treatment for Acute Radiation Syndrome (ARS) following selection by the U.S government National Institutes of Health's (NIH) Radiation and Nuclear Countermeasures Program (RNCP) for its radiation medical countermeasures Product Development Program  Opaganib is being developed for multiple additional indications, including COVID-19, acute respiratory distress syndrome (ARDS), filoviruses (including Ebola) and oncology TEL AVIV, Israel and RALEIGH, N.C. , Feb. 20, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

AGCO

Biogen

B2Gold

Ideal Power

Philip Morris

Stock turnarounds can happen when you least expect it. And with the opposite scenario imposing a rude awakening, it's time to at least consider last year's losers to make big splashes in 2024.

From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024

News for Gilead Sciences Stock (GILD)